Bausch + Lomb's experimental eye-drop treatment failed to reduce pain over the first 24 hours in a mid-stage trial involving 129 patients. The drug tested two doses on patients undergoing photorefractive keratectomy, a laser vision correction procedure. Shares fell 1.4% in extended trading on Thursday afternoon following the trial setback.

Despite missing its primary goal, the treatment showed secondary benefits. Complete pain relief at six hours reached 14% and 14.6% across the two doses, compared with 3.7% for placebos.